Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. - Université de Lorraine Access content directly
Journal Articles Advances in Therapy Year : 2023

Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.

Abstract

Introduction: Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system. Methods: A budget impact model was developed to estimate the 5-year implications of incorporating gliflozins in the treatment of patients with CKD in France, using efficacy data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial. Direct medical costs associated with drug acquisition and management, treatment-related adverse events, dialysis and kidney transplantation, and adverse clinical outcomes were considered. Market share forecasts were estimated from historical data and expert opinions. Event rates were derived from trial data, while cost data were sourced from published estimates. Results: The introduction of gliflozins was estimated to be cost saving compared to the no gliflozins scenario, with an expected cumulative 5-year budget impact of -€650 million, driven by slowed disease progression in patients treated with gliflozins, with fewer patients cumulatively progressing to end-stage kidney disease (84,526 vs. 92,062). This, in addition to fewer hospitalisations for heart failure and deaths from any cause, led to substantial medical care cost offsets (kidney-related: - €894 million; hospitalisation for heart failure: - €14.3 million; end-of-life care: - €17.3 million) to the additional drug acquisition (€273 million) and treatment-related adverse events costs (€2.98 million). Conclusion: In concert with early diagnosis and proactive management of CKD, the expansion of the gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications which outweighs the additional cost of the new treatment. INFOGRAPHIC.
Fichier principal
Vignette du fichier
s12325-023-02574-2.pdf (1.17 Mo) Télécharger le fichier
12325_2023_2574_MOESM1_ESM.pdf (431.1 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY NC - Attribution - NonCommercial
Licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-04138589 , version 1 (23-06-2023)

Licence

Attribution - NonCommercial

Identifiers

Cite

Gérard de Pouvourville, Patrick Rossignol, Meriem Boussahoua, Julie Chevalier, Peter Gabb, et al.. Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.. Advances in Therapy, 2023, 40 (9), pp.3751-3769. ⟨10.1007/s12325-023-02574-2⟩. ⟨hal-04138589⟩
43 View
32 Download

Altmetric

Share

Gmail Facebook X LinkedIn More